Scarica l'app Stockscreener
0.518
5.09%
-0.0278
Dopo l'orario di chiusura:
.52
0.002
+0.39%
Precedente Chiudi:
$0.5458
Aprire:
$0.5328
Volume 24 ore:
1.01M
Relative Volume:
0.10
Capitalizzazione di mercato:
$14.85M
Reddito:
-
Utile/perdita netta:
$-11.38M
Rapporto P/E:
-0.0187
EPS:
-27.73
Flusso di cassa netto:
$-12.72M
1 W Prestazione:
-2.65%
1M Prestazione:
-29.04%
6M Prestazione:
+204.53%
1 anno Prestazione:
-95.61%
Intervallo 1D:
$0.5104
$0.559
Intervallo di 1 settimana:
$0.502
$0.5915
Portata 52W:
$0.0915
$13.24
Windtree Therapeutics Inc Stock (WINT) Company Profile
Nome
Windtree Therapeutics Inc
Settore
Industria
Telefono
(215) 488-9300
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Confronta WINT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.518 | 6.50M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-26 | Iniziato | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
Windtree Therapeutics Presents Promising Interim Data for Istaroxime in Phase 2 Study of SCAI Stage C Cardiogenic Shock at HFSA Annual Meeting - Quiver Quantitative
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 - The Manila Times
Promising Phase 2 Results: New Drug Shows Hope for Fatal Heart Condition with 30% Mortality Rate - Stock Titan
Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results - MSN
Institutional Tools Highlight Unusual Flow in Windtree Therapeutics Inc.Stable Entry High Return Opportunities in Focus - beatles.ru
Windtree Therapeutics' Strategic Shift in Clinical Development and Its Implications for Istaroxime's Future - AInvest
Windtree Therapeutics Terminates SEISMiC-C Clinical Study - TipRanks
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MSN
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics Reveals Promising Phase 2 Study Data - The Globe and Mail
Windtree Therapeutics Incannounces interim analysis of istaroxime Phase 2 Study - MarketScreener
Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative
Breakthrough Clinical Data: Istaroxime Phase 2 Trial Advances Heart Failure Treatment to Phase 3 - Stock Titan
Windtree Therapeutics Appoints New Audit Committee Chair - TipRanks
WINT 8-K: Audit Chair Resigns, New Independent Director Appointed | NJR SEC FilingForm 8-K - Stock Titan
WINT 8-K: Audit Chair Changes Hands; Andrew Kucharchuk Joins Board | WINT SEC FilingForm 8-K - Stock Titan
BNB gaining mainstream acceptance, with companies like Nano Labs and Windtree Therapeutics allocating it to their treasuries. - AInvest
Windtree Therapeutics Stock Soars 10.5% on R&D Progress - AInvest
What are analysts’ price targets for Windtree Therapeutics Inc. in the next 12 monthsReal-time trading signals for maximum returns - Jammu Links News
How does Windtree Therapeutics Inc. generate profit in a changing economyInvest smarter with daily market updates - Jammu Links News
Is it the right time to buy Windtree Therapeutics Inc. stockConsistent wealth multiplication - Jammu Links News
How volatile is Windtree Therapeutics Inc. stock compared to the marketFree Smart Trading Workshop - Jammu Links News
When is Windtree Therapeutics Inc. stock expected to show significant growthAchieve remarkable returns with smart investing - Jammu Links News
What is the dividend policy of Windtree Therapeutics Inc. stockBuild a diversified portfolio for risk management - Jammu Links News
Windtree Therapeutics Inc. Stock Analysis and ForecastDiscover undervalued stocks before they soar - Jammu Links News
What catalysts could drive Windtree Therapeutics Inc. stock higher in 2025Accelerate your capital gains today - Jammu Links News
How does Windtree Therapeutics Inc. compare to its industry peersConsistently high returns - jammulinksnews.com
Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout - MSN
Sentiment Turns Positive on Windtree Therapeutics Inc. — Reversal AheadAI Powered High Return Stock Calls Dominate Watchlists - metal.it
MACD Cross Could Confirm Trend in Windtree Therapeutics Inc.Confirmed Setup With Expert Accuracy Supported - beatles.ru
Will wint go up tomorrow? - AInvest
Windtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency Holdings - MSN
What makes Windtree Therapeutics Inc. stock price move sharplyAccurate Buy Point for Momentum Stocks Detected - beatles.ru
RSI Reset May Fuel Rebound in Windtree Therapeutics Inc.Weekly Return Pick Forecast Reports Show Trend - metal.it
How Interest Rate Changes Impact Windtree Therapeutics Inc. Stock PerformanceChart-Based Trade Entries Gain Analyst Support - metal.it
Bitcoin News Today: Windtree Therapeutics Secures $520 Million to Expand BNB Treasury Strategy to $700 Million - AInvest
Why Windtree Therapeutics Inc. stock attracts strong analyst attentionWeekly Top Gainers Forecast Watchlist Released - beatles.ru
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption - The Manila Times
Windtree Therapeutics Announces Significant Redemption and Conversion of Preferred Shares, BNB Coin Value Increases Following Crypto Treasury Agreement - Quiver Quantitative
Windtree Eliminates 99% of Preferred C Shares as BNB Crypto Strategy Sees 17% Gain - Stock Titan
Windtree Therapeutics Inc. Sees Spike in Bullish Option FlowLow Capital High Return Stock Plans Reviewed - metal.it
Screener Results Flag Windtree Therapeutics Inc. as OversoldAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
Will Windtree Therapeutics Inc. stock benefit from AI tech trendsDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
Should I hold or sell Windtree Therapeutics Inc. stock in 2025Consistently superior profits - Jammu Links News
Windtree Taps Kraken to Power BNB Crypto Treasury Strategy - MSN
What institutional investors are buying Windtree Therapeutics Inc. stockBuild a winning portfolio with smart picks - jammulinksnews.com
Sectors Driving Future Growth for Windtree Therapeutics Inc. StockSolid Return Trade Selections - metal.it
Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):